Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A growing body of scientific evidence and data from the VIA-2291 clinical program points to reduction of inflammation and inflammatory processes in the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart attack and stroke.

"Our clinical trial results presented at the most recent meeting of the American Heart Association in New Orleans provides important evidence for VIA-2291's effect on reducing vascular inflammation. This patent is an important step in the commercial development of the compound by providing VIA with exclusivity in this very large and underserved market through 2026," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candida
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
(Date:8/27/2014)... --  MSC , a healthcare performance improvement company advancing ... of Mary Beth Loesch to President and ... preparing companies for rapid growth and market expansion, Loesch ... Corporate Development and Healthcare. In that role, she oversaw ... as corporate strategy and marketing. Previously, Loesch served as ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it ... enrolment in its U.S. Phase II trial to,evaluate ... sarcomas that have metastasized to the lung., ... full enrolment of 52,patients, Oncolytics had to demonstrate ...
... engineers at the University of California, Berkeley, may be the ... hairs that allow the tiny lizard to scamper along vertical ... adhesive could one day be used to outfit a small ... from the millions of hairs covering a gecko,s toes, researchers ...
... PALO ALTO, Calif., Jan. 30 CV Therapeutics,Inc. (Nasdaq: ... fourth quarter and,year end financial results for 2007 after ... will webcast a conference call at,5:00 p.m. EST, 2:00 ... the live webcast, please log on to the Company,s ...
Cached Biology Technology:Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 2Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 3New adhesive mimics gecko toe hairs 2New adhesive mimics gecko toe hairs 3CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2
(Date:8/27/2014)... Calif. , Aug. 27, 2014  WaferGen Bio-systems, ... its previously announced underwritten public offering of units of ... per unit for gross proceeds of $20 million, prior ... payable by the Company.  The shares and warrants are ... Each unit sold in the offering consists of ...
(Date:8/27/2014)... step in understanding the mysteries of the human genome ... that provide the most detailed comparison yet of how ... function. , The research, appearing August 28 in ... information encoded in the three species, genomes is "read ... into chromosomes. , The results add billions of entries ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Law Enforcement Biometrics Market ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About Biometrics Biometrics is ... the basis of their physical or behavioral patterns. ... physiological traits such as fingerprints, face recognition, DNA, ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... England are too hot to grow vines for making wine ... May 2008). The author, Emeritus Professor Richard Selley ... in the UK continue to rise as predicted, the Thames ... contain many vineyards, will be too hot to support wine ...
... the largest baby boom ever documented for the stock, with ... With typical annual averages of 50 to 100 million new ... puzzled by the huge increase and its ramifications for stock ... found one - healthy adults. In a study to ...
... have a unique ability to eat toxic mulberry leaves ... closer to understanding why: silkworms contain a special digestive ... Mulberry leaves contain an extremely high amount of ... and thus are potentially quite toxic. However, one type ...
Cached Biology News:Research suggests parts of UK could be too hot for wine making by 2080 2Healthy parents provide clues to survival of young haddock on Georges Bank 2
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
a1-Antitrypsin (human, alpha-1 AT)...
... The 7500ce meets the demands of the ... high performance from reliable, robust and simple ... detection power in the most challenging sample ... is equally suited to the toughest analytical ...
Biology Products: